AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Repaglinide
Description: Tablet corresponding to 1 mg; two tablets three times daily.
Study NCT02346630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules daily for 3 weeks.
Study NCT02346630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa / Carbidopa
Description: Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
Study NCT02346630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armeo
Description: Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
Study NCT02346630 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Armeo
Description: Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
Study NCT00111345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines
Description: 3x12 mg/qm
Study NCT00111345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin
Description: 3x80 mg/qm
Study NCT02234388 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: There are no interventions associated with this registry as it is purely observational.
Study NCT03210311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression
Description: a compression stocking is worn, a garment compression class 2, flat knitted
Study NCT02919683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02919683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02919683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Surgery
Study NCT00111345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-CDA
Description: 2x6 mg/qm
Study NCT00111345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: AI
Study NCT03275662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Study NCT03275662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Study NCT04250636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS at 30mg/kg
Study NCT04273594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc
Description: Treatment with FemBloc for women who desire permanent birth control (female sterilization)
Study NCT03447470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
Study NCT03447470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1
Study NCT02112474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
Study NCT02112474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 1
Description: 9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
Study NCT02112474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2
Description: 9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
Study NCT01644006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
Study NCT03537248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASP-57
Description: an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
Study NCT03537248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu® Multiplus
Description: a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
Study NCT04053946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Wounds Gels
Description: SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
Study NCT02857543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Diet
Study NCT02857543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association Diet
Study NCT03922347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening program including 2 consecutive tests
Description: visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
Study NCT03922347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening program with mobile health
Description: Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
Study NCT03359785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 Tablets.
Study NCT04250636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS at 30mg/kg
Study NCT03021512 — intervention group
Intervention type: PROCEDURE
Intervention: Phaco with Restor
Description: Phacoemulsification with bilateral bifocal intraocular lenses implantation
Study NCT02857543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Study NCT02231541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very Low Frequency Magnetic Fields
Description: The device is set to an analgesic program lasting about 30 minutes.
Study NCT02231541 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Very Low Frequency Magnetic Fields
Description: The device is turned off.
Study NCT03158376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT03158376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00290888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty
Study NCT00290888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acromioplasty
Study NCT00677612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
Study NCT02407821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
Study NCT02407821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
Study NCT04563923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avdoralimab (IPH5401)
Description: Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
Study NCT04563923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion
Study NCT00435292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: nonsteroidal anti-inflammatory drug
Study NCT00435292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid 250 mg
Description: flavonoid mixture
Study NCT00435292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavocoxid 500 mg
Description: flavonoid mixture
Study NCT02316808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol ester
Description: Smoothie that contains plant stanol ester
Study NCT03359785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo Tablets.
Study NCT03021512 — intervention group
Intervention type: PROCEDURE
Intervention: Phaco with Panoptix
Description: Phacoemulsification with bilateral trifocal intraocular lenses implantation
Study NCT03209700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
Study NCT02316808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Smoothie that contains placebo
Study NCT03156543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jumpstart Dressing
Description: JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B
Study NCT03828799 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Folfirinox + regorafenib
Description: folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
Study NCT02876107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02876107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02876107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00724854 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling
Study NCT00724854 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered in accordance with approved labeling
Study NCT04552639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newbridge Eating disorders Activity Treatment group
Description: A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
Study NCT04552639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newbridge House treatment as usual
Description: Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
Study NCT02224287 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technologist control of fluoroscopy
Description: Technologist control of fluoroscopy
Study NCT02224287 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgeon control of fluoroscopy
Description: Surgeon control of fluoroscopy
Study NCT04314999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Examination of stool samples
Description: Tests for diagnosis of parasitic diseases
Study NCT04234529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AMATEA™
Description: AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine.
Study NCT04234529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 1.08g of microcellulose and 270mg of caffeine.
Study NCT04234529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.35g of microcellulose
Study NCT02974959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore active device
Description: The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
Study NCT02974959 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore sham device
Description: The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
Study NCT02135328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Story
Description: For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management.
Study NCT02135328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio brochure
Description: The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
Study NCT04360239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
Study NCT00709293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
Study NCT00709293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
Study NCT01378702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mistletoe preparations
Description: 1 ampoule (1ml) twice per week subcutaneously
Study NCT01378702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mistletoe preparations
Description: 1 ampoule (1ml) twice per week subcutaneously
Study NCT03215303 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
Study NCT03215303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
Study NCT02918461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging from the Haze class
Description: A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
Study NCT02035436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation
Description: Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
Study NCT02035436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Sedation
Description: Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
Study NCT03172962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
Study NCT03172962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care (control)
Description: Will receive the usual care at the hospital
Study NCT03172962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (control)
Description: Will receive the usual care at the hospital
Study NCT02010333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ha44 Gel 0.74% w/w
Description: HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
Study NCT03479294 — intervention group
Intervention type: DRUG
Intervention: Shenlingcao Oral Liquid
Description: Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
Study NCT04956315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (reproducibility)
Description: The experienced examiner performed tests on 20 healthy subjects
Study NCT04956315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (availability)
Description: Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
Study NCT04956315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (Accuracy)
Description: 200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
Study NCT01493102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Vasopressin will be reduced first (0.01 U/hour)
Study NCT01493102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
Study NCT02338895 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound of inferior vena cava and kidneys
Study NCT00404755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
Study NCT00404755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
Study NCT00404755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipramine
Description: imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
Study NCT02174029 — intervention group
Intervention type: PROCEDURE
Intervention: Ventilation- mandatory
Description: Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
Study NCT02174029 — intervention group
Intervention type: PROCEDURE
Intervention: Ventilation- voluntary mode only
Description: Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
Study NCT02174029 — intervention group
Intervention type: PROCEDURE
Intervention: Voluntary with preceding mandatory
Description: Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.